Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 16/20 | 0.70 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23952209 | 0.92 | NLRP3 (0.74) | NLRP3DHODHTSHRHTTSMN1; SMN2 | |
| SCHEMBL23952397 | 0.90 | NLRP3 (0.71) | NLRP3DHODH | |
| SCHEMBL30059642 | 0.90 | NLRP3 (0.71) | NLRP3DHODH | |
| SCHEMBL23925463 | 0.90 | NLRP3 (0.71) | NLRP3DHODHTSHRHTTSMN1; SMN2 | |
| SCHEMBL23925340 | 0.88 | NLRP3 (0.68) | NLRP3DHODHTSHRHTTSMN1; SMN2 | |
| SCHEMBL23952073 | 0.88 | NLRP3 (0.68) | NLRP3DHODHTSHRHTTSMN1; SMN2 | |
| SCHEMBL23925594 | 0.84 | NLRP3 (0.78) | NLRP3DHODHTSHRHTTSMN1; SMN2 | |
| SCHEMBL23952442 | 0.84 | NLRP3 (0.80) | NLRP3DHODHTSHRHTTSMN1; SMN2 | |
| SCHEMBL25818822 | 0.84 | NLRP3 (0.80) | NLRP3DHODHTSHRHTTSMN1; SMN2 | |
| SCHEMBL30380673 | 0.83 | NLRP3 (0.62) | NLRP3HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183248-A1 | PYRROLO[1,2-D][1,2,4]TRIAZINE-2-YL-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183248-A1 | PYRROLO[1,2-D][1,2,4]TRIAZINE-2-YL-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY | NLRP3, NLRP1, IL1B | NLRP3 1/4885DHODH 1822/4885TSHR 4216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.